Dr. Abraham M. Korman, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 549
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: University of Cincinnati College of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
OH license 35.140976
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 549
- Services billed
- 1,491
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 253 | 42 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 158 | 152 |
| Established patient office or other outpatient visit, 30-39 minutes | 128 | 79 |
| Established patient office or other outpatient visit, 20-29 minutes | 86 | 71 |
| Destruction of precancer skin growth, 1 growth | 72 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 55 | 36 |
| New patient office or other outpatient visit, 30-44 minutes | 42 | 42 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 38 | 37 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
| Biopsy of related skin growth, first growth | 36 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Gahanna, OH | 117 |
| Dupixent Syringe (dupilumab) Other prescribers in Gahanna, OH | 70 |
| Clobetasol Propionate Other prescribers in Gahanna, OH | 67 |
| Prednisone Other prescribers in Gahanna, OH | 63 |
| Triamcinolone Acetonide Other prescribers in Gahanna, OH | 62 |
| Ketoconazole Other prescribers in Gahanna, OH | 57 |
| Mycophenolate Mofetil Other prescribers in Gahanna, OH | 50 |
| Minoxidil Other prescribers in Gahanna, OH | 44 |
| Dapsone | 41 |
| Methotrexate (methotrexate sodium) Other prescribers in Gahanna, OH | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $99.00 in total to this clinician.
| Janssen Biotech, Inc. | $99.00 |
|---|
| Education | $99.00 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 24, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $58,653 in research payments for these studies, mostly to the institutions running them.
- A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or In…
AstraZeneca UK Limited - P2 Moderate-Severe pDLE
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.